Navigation Links
Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/17/2011

NEW YORK, Oct. 17, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0656880/Depression-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global depression therapeutics market. The report identifies the key trends shaping and driving the global depression market. The report also provides insights in to the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights in to the pipeline products within the global depression market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData valued the global depression therapeutics market at $4.6 billion in 2010, and expects it to grow at a compound annual growth rate (CAGR) of 3.2% over the next seven years to reach $10.9 billion by 2018. The depression therapeutics market will witness the patent expiry of Lexapro in 2012, Cymbalta in 2013 and Effexor XR in 2014. However, the launch of new drugs such as Viibryd, LuAA21004, Levomilnacipran (F2695) and AGO178 (in the US), offering better efficacy and safety profiles, along with disease modifying properties, will help to sustain steady and positive growth during the forecast period to 2018.

Scope

The report provides information on the key drivers and challenges of the depression market. Its scope includes -

- Annualized global depression market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Glutamate receptor which includes Metabotropic glutamate receptors 2 antagonist, Glutamate receptor 2 and 3 antagonist, Group II metabotropic glutamate receptors antagonist, Metabotropic glutamate receptor 5 antagonist, N-methyl d-aspartate receptor (NMDAR) antagonist, Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) potentiator whereas Seretonin receptor modulators which includes 5-HT3, 5-HT7 and 5-HT1A receptor receptor agonist and 5-HT transporter inhibitor, 5-HT3 and 5-HT2C antagonist, 5HT reuptake blockade, 5HT2 agonism, 5HT1A agonism, and 5HT1D central receptors agonist, 5-HT2A/5-HT2C/D2/D3 receptor antagonist followed by Triple-reuptake inhibitors, Monoamine oxidase (MAO) modulators, Arginine vasopressin antagonists and so on.

- Analysis of the current and future competition in the global depression market. Key market players covered are Otsuka Holdings Co., Ltd, Forest Laboratories, H Lundbeck A/s, Eli Lilly, Targacept Inc., Fabre-Kramer Pharmaceuticals, Inc., Euthymics Bioscience, Inc., AstraZeneca PLC, and Novartis/Servier.

- An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the depression therapeutics market.

- Analysis of key recent licensing and partnership agreements in the depression therapeutics market.

Reasons to buy

The report will enhance your decision making capabilities. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

- Develop business strategies by understanding the trends shaping and driving the global depression market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global depression market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potential strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global depression market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Depression Therapeutics - Introduction 7

2.1 Disease Overview 7

2.2 Epidemiology 9

2.3 Etiology and Pathophysiology 11

2.4 Signs and Symptoms 14

2.5 Diagnosis 15

2.6 Treatment and Management Options 16

2.6.1 Referral Pathway 18

2.7 GlobalData Pipeline Report Guidance 19

3 Depression Therapeutics - Market Characterization 20

3.1 Overview 20

3.2 Depression Therapeutics Market Size (2005-2010) – Global 20

3.3 Depression Therapeutics Market Forecast (2010-2018) – Global 22

3.4 Depression Therapeutics Market Size (2005-2010) – The US 23

3.5 Depression Therapeutics Market Forecast (2010-2018) – The US 24

3.6 Depression Therapeutics Market Size (2005-2010) – France 25

3.7 Depression Therapeutics Market Forecast (2010-2018) – France 26

3.8 Depression Therapeutics Market Size (2005-2010) – Germany 27

3.9 Depression Therapeutics Market Forecast (2010-2018) – Germany 28

3.10 Depression Therapeutics Market Size (2005-2010) – Italy 29

3.11 Depression Therapeutics Market Forecast (2010-2018) – Italy 30

3.12 Depression Therapeutics Market Size (2005-2010) – Spain 31

3.13 Depression Therapeutics Market Forecast (2010-2018) – Spain 32

3.14 Depression Therapeutics Market Size (2005-2010) – The UK 33

3.15 Depression Therapeutics Market Forecast (2010-2018) – The UK 34

3.16 Depression Therapeutics Market Size (2005-2010) – Japan 35

3.17 Depression Therapeutics Market Forecast (2010-2018) – Japan 36

3.18 Drivers and Barriers for the Depression Therapeutics Market 37

3.18.1 Drivers for the Depression Therapeutics Market 37

3.18.2 Barriers for the Depression Therapeutics Market 37

3.19 Opportunity and Unmet Need Analysis 38

3.20 Key Takeaway 39

4 Depression Therapeutics: Competitive Assessment 40

4.1 Overview 40

4.1.1 Strategic Competitor Assessment 40

4.2 Product Profiles for the Major Marketed Products in the Depression Therapeutics Market 41

4.2.1 Selective Serotonin Reuptake Inhibitors (SSRIs) 41

4.2.2 Lexapro (escitalopram) 41

4.2.3 Viibryd (vilazodone hydrochloride) 43

4.2.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) 44

4.2.5 Cymbalta (duloxetine hydrochloride) 44

4.2.6 Pristiq (desvenlafaxine succinate) 45

4.2.7 Symbyax (olanzapine and fluoxetine combination) 46

4.3 Key Takeaway 48

5 Depression Therapeutics - Pipeline Assessment 49

5.1 Overview 49

5.2 Strategic Pipeline Assessment 49

5.3 Depression Therapeutics Pipeline – Pipeline by Phases of Development 49

5.3.1 Depression Therapeutics – Phase III Pipeline 50

5.3.2 Depression Therapeutics – Phase II Pipeline 50

5.3.3 Depression Therapeutics – Phase I Pipeline 51

5.3.4 Depression Market – Pre-Clinical Pipeline 52

5.3.5 Technology Trends Analytic Framework 52

5.4 Depression Therapeutics Market –Pipeline by Mechanism of Action 56

5.5 Depression Therapeutics – Promising Drugs under Clinical Development 57

5.6 Molecule Profile for Promising Drugs Under Clinical Development 57

5.6.1 Lu AA21004 57

5.6.2 TC-5214 58

5.6.3 AGO178 (agomelatine) 59

5.7 Key Takeaway 60

6 Depression Therapeutics - Clinical Trials Mapping 61

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 61

6.2 Clinical Trials by Phase 62

6.3 Clinical Trials by Trial Status 63

6.4 Prominent Sponsors 64

6.5 Top Companies Participating in Depression Therapeutics Clinical Trials 66

7 Strategic Assessment 67

7.1 Key Events Impacting the Future Market 67

7.2 Depression Therapeutics: Implications for Future Market Competition 68

8 Depression Therapeutics: Future Players 69

8.1 Introduction 69

8.2 Company Profiles 69

8.2.1 Lundbeck A/S 69

8.2.2 Novartis AG 71

8.2.3 AstraZeneca PLC 72

8.2.4 Eli Lilly and Company 74

8.2.5 Targacept Inc. 75

9 Depression Therapeutics - Licensing and Partnership Deals 77

10 Depression Therapeutics - Appendix 88

10.1 Market Definitions 88

10.2 Abbreviations 88

10.3 Methodology 89

10.3.1 Coverage 89

10.3.2 Secondary Research 90

10.3.3 Forecasting 90

10.3.4 Primary Research 92

10.3.5 Expert Panel Validation 93

10.4 Contact Us 93

10.5 Disclaimer 93

10.6 Bibliography 93

List of Tables

Table 1: Stages of Depression 7

Table 2: Depression Therapeutics Market, Global, Revenue ($bn), 2005–2010 21

Table 3: Depression Therapeutics Market, Global, Forecast ($bn), 2010–2018 22

Table 4: Depression Therapeutics Market, The US, Revenue ($m), 2005–2010 23

Table 5: Depression Therapeutics Market, The US, Forecast ($m), 2010–2018 24

Table 6: Depression Therapeutics Market, France, Revenue ($m), 2005–2010 25

Table 7: Depression Therapeutics Market, France, Forecast ($m), 2010–2018 26

Table 8: Depression Therapeutics Market, Germany, Revenue ($m), 2005–2010 27

Table 9: Depression Therapeutics Market, Germany, Forecast ($m), 2010–2018 28

Table 10: Depression Therapeutics Market, Italy, Revenue ($m), 2005–2010 29

Table 11: Depression Therapeutics Market, Italy, Forecast ($m), 2010–2018 30

Table 12: Depression Therapeutics Market, Spain, Revenue ($m), 2005–2010 31

Table 13: Depression Therapeutics Market, Spain, Forecast ($m), 2010–2018 32

Table 14: Depression Therapeutics Market, The UK, Revenue ($m), 2005–2010 33

Table 15: Depression Therapeutics Market, The UK, Forecast ($m), 2010–2018 34

Table 16: Depression Therapeutics Market, Japan, Revenue ($m), 2005–2010 35

Table 17: Depression Therapeutics Market, Japan, Forecast ($m), 2010–2018 36

Table 18: SSRIs Approved for Depression 41

Table 19: Summary of Results for the Primary Efficacy Endpoint 43

Table 20: SNRIs Approved for Depression 44

Table 21: MADRS Total Score Mean Change from Baseline to Endpoint 47

Table 22: Depression Therapeutics, Phase III Pipeline, 2011 50

Table 23: Depression Therapeutics, Phase II Pipeline, 2011 50

Table 24: Depression Therapeutics, Phase I Pipeline, 2011 51

Table 25: Depression Therapeutics, Pre-clinical Pipeline, 2011 52

Table 26: Depression Therapeutics – Most Promising Drugs Under Clinical Development, 2011 57

Table 27: Lu AA21004 Efficacy Measure 57

Table 28: Treatment-Related Adverse Events 58

Table 29: AGO178, Active Comparator Study 59

Table 30: Depression Therapeutics, Clinical Trials by Country, 2011 61

Table 31: Depression Therapeutics, Clinical Trials by Phase, 2011 62

Table 32: Depression Therapeutics, Clinical Trials by Status, 2011 63

Table 33: Depression Therapeutics, Overall Sponsors, 2011 64

Table 34: Depression Therapeutics, Prominent Sponsors, 2011 65

Table 35: Depression Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 66

Table 36: Lundbeck A/S – Depression, Pipeline Products, 2011 70

Table 37: Novartis, Depression Pipeline, 2011 72

Table 38: AstraZeneca PLC, Depression Pipeline, 2011 73

Table 39: Eli Lilly and Company, Depression Pipeline, 2011 74

Table 40: Targacept Inc., Depression Pipeline, 2011 76

Table 41: Depression Therapeutics, Global, Deals, 2009-2011 77

List of Figures

Figure 1: DSM-IV Diagnostic Criteria for Depression 8

Figure 2: Total Estimated Cost of Brain Disorders in Europe by Disease Area 10

Figure 3: Economic Burden Associated with Depression 10

Figure 4: Relationship Between Major Depression and Cardiovascular Disease 12

Figure 5: Serotonergic Systems in Alteration of Depression 13

Figure 6: Alterations of Noradrenergic Systems in Depression 13

Figure 7: Alterations of Dopaminergic Systems in Depression 14

Figure 8: Diagnostic Approach for Depression 15

Figure 9: Drug Classes for the Treatment of Depression 16

Figure 10: Treatment Algorithm 17

Figure 11: Referral Pathway for Depression 18

Figure 12: Depression Therapeutics Market, Global, Revenue ($bn), 2005–2010 20

Figure 13: Depression Therapeutics Market, Global, Forecast ($bn), 2010–2018 22

Figure 14: Depression Therapeutics Market, The US, Revenue ($m), 2005–2010 23

Figure 15: Depression Therapeutics Market, The US, Forecast ($m), 2010–2018 24

Figure 16: Depression Therapeutics Market, France, Revenue ($m), 2005–2010 25

Figure 17: Depression Therapeutics Market, France, Forecast ($m), 2010–2018 26

Figure 18: Depression Therapeutics Market, Germany, Revenue ($m), 2005–2010 27

Figure 19: Depression Therapeutics Market, Germany, Forecast ($m), 2010–2018 28

Figure 20: Depression Therapeutics Market, Italy, Revenue ($m), 2005–2010 29

Figure 21: Depression Therapeutics Market, Italy, Forecast ($m), 2010–2018 30

Figure 22: Depression Therapeutics Market, Spain, Revenue ($m), 2005–2010 31

Figure 23: Depression Therapeutics Market, Spain, Forecast ($m), 2010–2018 32

Figure 24: Depression Therapeutics Market, The UK, Revenue ($m), 2005–2010 33

Figure 25: Depression Therapeutics Market, The UK, Forecast ($m), 2010–2018 34

Figure 26: Depression Therapeutics Market, Japan, Revenue ($m), 2005–2010 35

Figure 27: Depression Therapeutics Market, Japan, Forecast ($m), 2010–2018 36

Figure 28: Opportunity and Unmet Need in the Depression Therapeutics Market, 2010 38

Figure 29: Depression Therapeutics, Strategic Competitor Assessment, 2010 40

Figure 30: Depression Therapeutics, Pipeline by Phase of Development, 2011 49

Figure 31: Approaches to the Development of Antidepressants Targeting Non Monoaminergic Components 53

Figure 32: Depression Therapeutics, Technology Trends Analytical Framework, 2011 54

Figure 33: Depression Therapeutics, Technology Trends Analytical Framework, Description, 2011 55

Figure 34: Depression Therapeutics, Pipeline by Mechanism of Action (%), 2011 56

Figure 35: Depression Therapeutics, Clinical Trials by Country, 2011 61

Figure 36: Depression Therapeutics, Clinical Trials by Phase (%), 2011 62

Figure 37: Depression Therapeutics, Clinical Trials by Status (%), 2011 63

Figure 38: Depression Therapeutics, Overall Sponsors (%), 2011 64

Figure 39: Depression Therapeutics, Prominent Sponsors (%), 2011 65

Figure 40: Depression Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 66

Figure 41: Depression Therapeutics Market, Drivers and Barriers, 2011 67

Figure 42: Implications for Future Market Competition in the Depression Market, 2011 68

Figure 43: Depression Therapeutics Market – Pipeline by Company, 2011 69

Figure 44: GlobalData Market Forecasting Model 92

Companies Mentioned

Lundbeck A/S

Novartis AG

AstraZeneca PLC

Eli Lilly and Company

Targacept Inc.

To order this report:

Pathology Industry: Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Phreesias Digital Depression Screening Improves Early Detection and Drives Better Healthcare Outcomes in Medical Practices
2. Potential Mechanism of Action Identified for the Treatment of Major Depression With Trigeminal Nerve Stimulation (TNS) - The USB Port to the Brain™
3. Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients
4. Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression
5. Neuralstem Updates NSI-189 Major Depression Trial
6. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
7. CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression
8. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
9. Omega-3 Supplements Show Promise in Alleviating Depression
10. The Welcome Back Awards Seeks Nominations to Honor Leaders in the Depression Community
11. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... PORTLAND, Ore. , Feb. 11, 2016 ... is pleased to announce the acquisition of SolutionsRx, a ... rural access hospitals. Along with providing traditional contract pharmacy ... services to assist clients in navigating the complex 340B ... CEO of Wellpartner. --> James R. Love ...
(Date:2/11/2016)... , 11 de fevereiro de 2016 /PRNewswire/ ... de sua fábrica de soroalbumina bovina (BSA -- ... A fábrica fica na Ilha Norte da Nova ... desenvolvido e estabelecido na fábrica da Proliant nos ... . O projeto e instalação dos equipamentos foram ...
(Date:2/11/2016)... M&A achieved through NPS and Dyax acquisitions and the announced ... through NPS and Dyax acquisitions and the announced combination with ... NPS and Dyax acquisitions and the announced combination with Baxalta ... pipeline in Shire , s history   ... in Shire , s history   --> ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Florida Hospital presents Heart Health Awareness ... St. Louis Blues at the Amalie Arena. The puck drops at 6:00pm, but fans ... the MEGA Heart, prior to the game. The MEGA Heart will be located on ...
(Date:2/11/2016)... ... 2016 , ... Hall Integrative Health and Chiropractic, PC which ... grand openings in March. All seven practices are set to start accepting patients ... diabetes possible? According to this 2011 CNN article it is possible: http://www.cnn.com/2011/HEALTH/01/28/reverse.diabetes/ ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... clinical decision support technology, with highly adaptable algorithms, has been updated to help ... has signs and symptoms consistent with Zikas and a travel history to affected ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... of a master charity program created to assist the people of their local ... closely with nonprofit organizations and community leaders. Their hope is to bring awareness ...
(Date:2/11/2016)... Rock, AR (PRWEB) , ... February 11, 2016 , ... ... in their community by announcing a new fundraiser in support of a local boy ... also hopes the campaign will bring awareness to, and rally support for, all local ...
Breaking Medicine News(10 mins):